Sunshine

Significance of the Topic

Lipid nanoparticles (LNPs) are essential carriers for modern therapeutics, including mRNA vaccines and gene delivery systems. Achieving precise control over particle size, uniformity, and stability during formulation and scale-up is critical for clinical and commercial applications. A streamlined platform that integrates high-throughput screening, process optimization, and scalable continuous manufacturing can accelerate development timelines and ensure reproducibility across scales.

Objectives and Overview of the Article

This article presents the Sunshine platform by Unchained Labs, designed to guide users from initial LNP formulation through process development to large-scale production. Key goals include enabling rapid screening of formulation variables, automated tuning of mixing and dilution parameters, and seamless transition to continuous flow mode for multi-liter outputs—all on one integrated system.

Methodology and Instrumentation

The Sunshine system combines programmable pumps, reusable glass microfluidic mixers (“Sunnies”), and dedicated Sunny Suite Software to automate LNP production:

• Sunny T: classic T-junction mixing for basic applications.
• Sunny X: cross-junction design providing larger fluid contact area and multiple channel sizes.
• Sunny Trident: reverse-angle mixing with in-line dilution capability for broad flow rate and ratio exploration.

Users load payload and lipid solutions into syringes, set lipid-to-payload ratios, total and fractional flow rates (0.1–30 mL/min), and desired dilution factor. The system supports sample volumes from 1 mL to continuous multi-liter mode, with minimal dead volume and integrated dilution for stable particle formation.

Main Results and Discussion

High-throughput experiments demonstrate the platform’s ability to generate ten distinct LNP samples in 15 minutes, enabling rapid exploration of flow rate, ratio, and dilution parameters. Data on DOTAP LNPs show:

• Decreasing Z-average size with increasing total flow rate, while maintaining low PDI (<0.2).
• Stable particle size and PDI across sequential aliquots during continuous runs, confirming process robustness for bulk production.

The Sunny Suite workflow—from the initial 96-well Sunscreen screening to Sunshine optimization and Sunbather GMP-compliant production—ensures consistent equipment and protocols throughout development.

Benefits and Practical Applications

The integrated Sunshine platform offers several advantages for analytical and process chemists:

• Rapid identification of optimal formulation and mixing conditions, reducing resource expenditure.
• Fully automated parameter sweeps with real-time software validation to prevent setup errors.
• Scalable continuous flow manufacturing with consistent quality from milliliter to liter scales.
• Smooth protocol transfer across modalities, minimizing revalidation efforts during scale-up and GMP transition.

Future Trends and Opportunities

Advancements likely to enhance LNP development include:

• Integration of in-line analytics (e.g., DLS, fluorescence) for real-time particle characterization and closed-loop control.
• Machine learning–driven optimization to predict optimal formulation parameters from historical data.
• Expansion to complex, multi-component LNP systems for co-delivery of nucleic acids and small molecules.
• On-demand, decentralized manufacturing systems for personalized medicine and point-of-care applications.

Conclusion

Unchained Labs’ Sunshine platform unifies high-throughput screening, process optimization, and scalable continuous manufacturing of lipid nanoparticles on a single system. Its modular microfluidic mixers, automated software controls, and seamless scale-up capabilities deliver reproducible particle characteristics from early R&D through GMP production, accelerating development and reducing risk in therapeutic delivery workflows.